Label (71610 815 41)
Brilinta Tablet
Product Images NDC 71610-815
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Brilinta (NDC 71610-815). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Aphena (Aphena)
Figure_1 (Figure 1)
The text describes a comparison between two medications, Tigomg and Clopidogrel, with regard to the number of patients experiencing events, the Kaplan-Meier percentage at 12 months, and the number of days from the first study drug dose. It provides information on patient numbers at risk for each drug at different time points. This data is relevant for evaluating the efficacy and outcomes of these medications in a study.*
Fiigure_2 (Figure 2)
Chemical Structure (Chemical Structure)
Figure_8 (Figure 08)
This is a medication chart providing information on drug interactions and recommendations for Ticagrelor AR-C124910XX. It includes details on interacting drugs such as strong CYP3A4 inhibitors like Ketoconazole, moderate CYP3A inhibitors like Diltiazem, and potent CYP3A4 inducers like Rifampin. The chart also mentions drugs like Aspirin, Desmopressin, Heparin, Enoxaparin, Cyclosporine, Morphine, and Fentanyl, along with instructions for dose adjustments and usage. It provides valuable insights into potential effects of these medications when used in conjunction with Ticagrelor AR-C124910XX.*
Figure_10 (Figure 10)
Figure_11 (Figure 11)
Figure_12 (Figure 12)
Figure_13 (Figure 13)
Figure_14 (Figure 14)
This text appears to include statistical data related to the evaluation of treatment effects and characteristics of the study participants. The information contains details such as the distribution of participants by age group, weight category, ethnicity, medical history, medication use, and various other factors. The data also includes the number of participants and outcomes related to the treatment with Ticagrelor versus a Placebo. It further provides Hazard Ratios (HR) with 95% Confidence Intervals (CI) for different variables. The text seems to be a detailed analysis or summary of a clinical study or trial comparing the efficacy of Ticagrelor and Placebo in a particular population.*
Figure_15 (Figure 15)
Figure_16 (Figure 16)
The text provides a detailed breakdown of patient characteristics in a study comparing ticagrelor versus placebo. It includes information such as demographics (age, sex, race), medical history (aspirin dose, HbA1c levels, eGFR, insulin use, history of angina, PCI, CABG, smoking status), and duration of diabetes among others. The analysis shows the hazard ratio (HR) with 95% confidence intervals for ticagrelor compared to placebo for different subgroups. This data can be useful in understanding how these factors may influence the effectiveness of ticagrelor in cardiovascular outcomes.*
Figure_17 (Figure 17)
The text provides data on the number of events recorded for Ticagrelor 90 mg bd and Placebo groups, as well as the number of participants at risk over time. This data can be used to analyze the effectiveness of the medication in reducing events compared to the placebo.*
Figure_18 (Figure 18)
The text provides details about the characteristics of patients involved in a clinical trial, including demographics, medical history, and outcomes related to the efficacy of Ticagrelor compared to placebo. It includes information on patient age, sex, race, geographic region, diagnosis, comorbidities such as diabetes mellitus and hypertension, as well as prior medical conditions. The data also presents the percentage of patients experiencing better outcomes with Ticagrelor compared to placebo, along with corresponding hazard ratios and 95% confidence intervals. The information may be used for further analysis and understanding of the effectiveness of Ticagrelor in the context of the study.*
Figure_3 (Figure 3)
This is a data snippet showing the numbers of participants at risk over time in a clinical trial comparing Ticagrelor against a Placebo. The number of participants receiving Ticagrelor starts with 9562 and gradually decreases over months, as does the number of participants receiving Placebo starting with 9531. The data presents the cumulative percentages at different time points from randomization, and the "N at risk" numbers progressively decrease as time passes.*
Figure_4 (Figure 4)
This is a table displaying cumulative percentages of events and natural risk days from randomization for different treatments. It includes data on Ticagrelor 90mg and Placebo treatments. The events are measured as a percentage of the total number of patients at various time points.*
Figure_5 (Figure 5)
Figure_6 (Figure 6)
Figure_7 (Figure 7)
Figure_9 (Image 09)
This text provides information about the interaction between Ticagrelor and different drugs, specifying the recommended doses and any required adjustments. It outlines the mean effect and 90% confidence interval along with recommendations for each combination. These details are crucial for clinicians to ensure the safe and effective use of Ticagrelor in patients taking other medications simultaneously.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
